Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
Eli Lilly expects its Alzheimer’s treatment donanemab to snag accelerated approval in the US “sometime in the coming months” and full approvals “sometime in ‘24” in major markets, including Japan, Chairman and CEO David A. Ricks told Jiho in an…
To read the full story
Related Article
- Lilly’s Alzheimer’s Therapy Filed in Japan, Approval Eyed in 2024
September 27, 2023
BUSINESS
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…